Lakefront Biotherapeutics NV

Company snapshot

Lakefront Biotherapeutics NV maintains 99 tracked programs across Cystic Fibrosis, Rheumatoid Arthritis, Ulcerative Colitis, Idiopathic Pulmonary Fibrosis, Osteoarthritis, Crohn's Disease, Systemic Lupus Erythematosus, Atopic Dermatitis, Ankylosing Spondylitis, Bioavailability, Fistulizing Crohn's Disease, Inflammatory Bowel Disease. Momentum score: 20/100 (30-day delta: n/a). Public registry data

• 99 active pipeline program(s) linked via ClinicalTrials.gov.
• 99 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lakefront Biotherapeutics NV. Not investment advice.

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 42.4

• Peer + 0 momentum

  Ultragenyx UK

  TA overlap score 40

• Peer + 0 momentum

  Vertex Pharmaceuticals (Australia)

  TA overlap score 40

• Peer + 0 momentum

  Takeda

  TA overlap score 40

• Peer + 0 momentum

  AbbVie

  TA overlap score 38.2

• Peer + 0 momentum

  Gilead Sciences Ireland

  TA overlap score 35.2

• Peer + 0 momentum

  Protalix Biotherapeutics

  TA overlap score 34.2

• Peer + 0 momentum

  RIGEL PHARMACEUTICALS

  TA overlap score 27.2

• Peer + 0 momentum

  Aclaris Therapeutics

  TA overlap score 26.6

• Peer + 0 momentum

  Corbus Pharmaceuticals

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Lakefront Biotherapeutics NV.

1. Jun 8, 2026 Clinical update

   PEG-liposomal prednisolone sodium phosphate — Phase 2

2. Jun 8, 2026 Clinical update

   GLPG3970 film-coated tablet — Phase 1

3. Jun 8, 2026 Clinical update

   GLPG CAR T-cell therapy — Phase 3

4. Jun 8, 2026 Clinical update

   Atorvastatin — Phase 1

5. Jun 8, 2026 Clinical update

   500 mg GLPG1837 as oral suspension — Phase 1

View all clinical trial activity →

• What is Lakefront Biotherapeutics NV?

  LAVA Therapeutics N.V is a pharma organization headquartered in Utrecht, NL. It trades on NYSE under ticker LKFT. Primary therapeutic focus areas include Cystic Fibrosis, Rheumatoid Arthritis, Ulcerative Colitis, Idiopathic Pulmonary Fibrosis, Osteoarthritis. NovaPharmaNews links

• Is Lakefront Biotherapeutics NV publicly traded?

  Yes. Lakefront Biotherapeutics NV is listed with ticker LKFT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Lakefront Biotherapeutics NV develop or market?

  We link 26 drug profile(s) where Lakefront Biotherapeutics NV is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lakefront-biotherapeutics-nv#company-drugs.

• What are the latest developments for Lakefront Biotherapeutics NV?

  In the last 12 months our linked public records show 99 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lakefront Biotherapeutics NV focus on?

  Lakefront Biotherapeutics NV focuses on Cystic Fibrosis, Rheumatoid Arthritis, Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.